๐ฅ๐ฒ๐ด๐๐น๐ฎ๐๐ผ๐ฟ๐ ๐๐น๐ฒ๐ฟ๐: ๐ ๐๐ก ๐๐ฒ๐ฎ๐ฑ๐น๐ถ๐ป๐ฒ ๐๐ ๐๐ฒ๐ฟ๐ฒ. ๐๐ ๐ฌ๐ผ๐๐ฟ ๐ง๐ฒ๐ฎ๐บ ๐ฅ๐ฒ๐ฎ๐ฑ๐ ๐ณ๐ผ๐ฟ ๐ช๐ต๐ฎ๐ ๐๐ผ๐บ๐ฒ๐ ๐ก๐ฒ๐ ๐?
June 11 marks the end of the voluntary compliance window under the Most-Favored-Nation (MFN) Executive Order.
If your organization hasnโt finalized a pricing strategy, the time for preemptive planning is over. But itโs not too late to respond strategically.
๐ช๐ต๐ฎ๐ ๐ต๐ฎ๐ฝ๐ฝ๐ฒ๐ป๐ ๐ป๐ผ๐? While the next steps from regulators are not fully defined, the EO outlines potential enforcement actions, including:
โช๏ธ ๐๐ฟ๐๐ด ๐ถ๐บ๐ฝ๐ผ๐ฟ๐๐ฎ๐๐ถ๐ผ๐ป ๐๐ป๐ฑ๐ฒ๐ฟ ๐๐ฒ๐ฐ๐๐ถ๐ผ๐ป ๐ด๐ฌ๐ฐ
โช๏ธ ๐๐
๐ฝ๐ผ๐ฟ๐ ๐ฝ๐ผ๐น๐ถ๐ฐ๐ ๐ฟ๐ฒ๐๐ถ๐ฒ๐๐
โช๏ธ ๐๐ป๐๐ถ๐๐ฟ๐๐๐ ๐ถ๐ป๐๐ฒ๐๐๐ถ๐ด๐ฎ๐๐ถ๐ผ๐ป๐
โช๏ธ ๐๐๐ฒ๐ป ๐ฝ๐ผ๐๐๐ถ๐ฏ๐น๐ฒ ๐ฟ๐ฒ๐๐ผ๐ฐ๐ฎ๐๐ถ๐ผ๐ป ๐ผ๐ณ ๐ฑ๐ฟ๐๐ด ๐ฎ๐ฝ๐ฝ๐ฟ๐ผ๐๐ฎ๐น๐
๐ง๐ต๐ถ๐ ๐บ๐ฎ๐ธ๐ฒ๐ ๐ฝ๐ฟ๐ถ๐ฐ๐ถ๐ป๐ด ๐ฎ๐ด๐ถ๐น๐ถ๐๐ ๐ฎ๐ป๐ฑ ๐ฝ๐ฎ๐๐ฒ๐ฟ ๐ถ๐ป๐๐ถ๐ด๐ต๐ ๐บ๐ผ๐ฟ๐ฒ ๐ฐ๐ฟ๐ถ๐๐ถ๐ฐ๐ฎ๐น ๐๐ต๐ฎ๐ป ๐ฒ๐๐ฒ๐ฟ.
๐๐ฒ๐ฟ๐ฒโ๐ ๐๐ต๐ฎ๐ ๐๐ผ๐ ๐ฐ๐ฎ๐ป ๐ฑ๐ผ ๐๐ผ๐ฑ๐ฎ๐:
๐ญ. ๐จ๐๐ฒ ๐ ๐๐ฉ๐ยฎ to gather payer sentiment and validate price thresholds
๐ฎ. ๐๐ฒ๐๐ฒ๐ฟ๐ฎ๐ด๐ฒ ๐๐น๐ฎ๐๐๐ถ๐ฐ๐ถ๐๐โข to test fallback scenarios and model pricing impacts
๐ฏ. ๐จ๐๐ฒ ๐๐ผ๐ป๐๐ฟ๐ฎ๐ฐ๐๐ถ๐ป๐ด ๐ฅ๐ข๐ to assess rebate tradeoffs and negotiation risks
๐ฐ. ๐ง๐ฟ๐ฎ๐ฐ๐ธ ๐ด๐น๐ผ๐ฏ๐ฎ๐น ๐บ๐ฎ๐ฟ๐ธ๐ฒ๐ ๐๐ต๐ถ๐ณ๐๐ ๐๐ถ๐๐ต ๐ฆ๐๐ข๐ฅ๐โข to stay one step ahead
At eMAX Health, weโre helping pharma clients answer the hard questions quickly.
Download our MFN Readiness Guide
Contact us to set up a response strategy session.